PMID- 33010280
OWN - NLM
STAT- MEDLINE
DCOM- 20201204
LR  - 20201214
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 262
DP  - 2020 Dec 1
TI  - Phosphoesterase complex modulates microflora and chronic inflammation in rats 
      with alcoholic fatty liver disease.
PG  - 118509
LID - S0024-3205(20)31262-5 [pii]
LID - 10.1016/j.lfs.2020.118509 [doi]
AB  - Phosphoesterase complex (Pho), a major active component of barley malt, has been 
      demonstrated to be clinically effective in relieving alcoholic fatty liver 
      disease (AFLD), and several lines of evidence have suggested that microbial 
      dysbiosis, caused by chronic alcohol overconsumption, plays a key role in the 
      progression of AFLD. The current study aimed to investigate the modulatory effect 
      of Pho on gut microflora. The microbiota diversity, determined via detection of 
      the V4 region of 16S rDNA genes, was analyzed in rats fed the Lieber-Decarli 
      diet. Gut permeability was evaluated via mucus layer staining. 
      Dysbiosis-associated chronic inflammation was investigated by observing the 
      expression of the following inflammatory molecules in the liver: tumor necrosis 
      factor alpha (TNF-alpha), monocyte chemotactic protein 1 (MCP-1), chemokine (C-X-C motif) 
      ligand 1 (CXCL-1) and interleukin 1 beta (IL-1beta). Pyrosequencing revealed that 
      the gut microbiota in Pho-treated rats was different from that of AFLD rats at 
      both the phylum and genus levels. In addition, Pho significantly alleviated 
      dysbiosis-associated disruption of gut permeability and inflammation, increased 
      mucus layer thickness and downregulated TNF-alpha, MCP-1, CXCL-1 and IL-1beta 
      expression. In summary, the current results revealed that the microflora, gut 
      barrier and chronic inflammation in AFLD may be modulated by Pho.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Ma, Di
AU  - Ma D
AD  - Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University 
      School of Medicine, Shanghai 200025, China.
FAU - Hu, Jie
AU  - Hu J
AD  - Qingdao Huanghai Pharmaceutical Co., Ltd, Shangdong 266101, China.
FAU - Xu, Wenqi
AU  - Xu W
AD  - China State Institute of Pharmaceutical Industry, Shanghai 200040, China; State 
      Key Laboratory of New Drug & Pharmaceutial Process, Shanghai Institute of 
      Pharmaceutical Industry, Shanghai 200437, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - China State Institute of Pharmaceutical Industry, Shanghai 200040, China; State 
      Key Laboratory of New Drug & Pharmaceutial Process, Shanghai Institute of 
      Pharmaceutical Industry, Shanghai 200437, China.
FAU - Wang, Juan
AU  - Wang J
AD  - China State Institute of Pharmaceutical Industry, Shanghai 200040, China; State 
      Key Laboratory of New Drug & Pharmaceutial Process, Shanghai Institute of 
      Pharmaceutical Industry, Shanghai 200437, China.
FAU - Li, Liang
AU  - Li L
AD  - China State Institute of Pharmaceutical Industry, Shanghai 200040, China; State 
      Key Laboratory of New Drug & Pharmaceutial Process, Shanghai Institute of 
      Pharmaceutical Industry, Shanghai 200437, China.
FAU - Wang, Sheng
AU  - Wang S
AD  - China State Institute of Pharmaceutical Industry, Shanghai 200040, China; State 
      Key Laboratory of New Drug & Pharmaceutial Process, Shanghai Institute of 
      Pharmaceutical Industry, Shanghai 200437, China.
FAU - Zhou, Huiping
AU  - Zhou H
AD  - Department of Pharmacology, School of Pharmacy, Guilin Medial University, Guilin 
      541001, Guangxi, China.
FAU - Li, Yuhua
AU  - Li Y
AD  - Department of Microbial and Biochemical Pharmacy, School of Pharmacy, Southwest 
      Medial University, Luzhou 646000, Sichuan, China; Department of Pharmacology, 
      School of Pharmacy, Guilin Medial University, Guilin 541001, Guangxi, China. 
      Electronic address: yuhualee973@126.com.
FAU - Liu, Li
AU  - Liu L
AD  - China State Institute of Pharmaceutical Industry, Shanghai 200040, China; State 
      Key Laboratory of New Drug & Pharmaceutial Process, Shanghai Institute of 
      Pharmaceutical Industry, Shanghai 200437, China. Electronic address: 
      liuli1129@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20200930
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Enzymes)
SB  - IM
MH  - Animals
MH  - Disease Models, Animal
MH  - Dysbiosis/*drug therapy/microbiology/physiopathology
MH  - Enzymes/isolation & purification/pharmacology
MH  - Fatty Liver, Alcoholic/*drug therapy/microbiology/physiopathology
MH  - Gastrointestinal Microbiome
MH  - Hordeum/*chemistry/enzymology
MH  - Inflammation/*drug therapy/microbiology/pathology
MH  - Male
MH  - Rats
MH  - Rats, Wistar
OTO - NOTNLM
OT  - Alcoholic fatty liver disease
OT  - Chronic inflammation
OT  - Gut barrier
OT  - Microflora
OT  - Phosphoesterase complex
EDAT- 2020/10/04 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/10/03 20:08
PHST- 2020/06/28 00:00 [received]
PHST- 2020/09/07 00:00 [revised]
PHST- 2020/09/24 00:00 [accepted]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/10/03 20:08 [entrez]
AID - S0024-3205(20)31262-5 [pii]
AID - 10.1016/j.lfs.2020.118509 [doi]
PST - ppublish
SO  - Life Sci. 2020 Dec 1;262:118509. doi: 10.1016/j.lfs.2020.118509. Epub 2020 Sep 
      30.